NCT00619424View on ClinicalTrials.gov

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 15, 2007

Primary Completion Date

September 4, 2009

Study Completion Date

September 4, 2009

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

pazopanib

Oral tablet administered daily in dosages of 400 - 800 mg.

DRUG

erlotinib

oral tablet taken daily in dosages of 100-150 mg.

DRUG

pemetrexed

IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2

Trial Locations (4)

10043

GSK Investigational Site, Orbassano (TO)

14263

GSK Investigational Site, Buffalo

37203

GSK Investigational Site, Nashville

80045

GSK Investigational Site, Aurora

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00619424 - A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter